RE: Cardiomyopathy3 Feb 2022 10:14
In the UK the BNF is the holy grail of drug information. The clinicians would definately be following the guidlines in the BNF rather than American guidance. Even so, if the initial trial has 3 doses all at the doses you stated, it is looking VERY promising that at 486mg/m2 the safety data permits the dosage to be escalated. As currently treatment would be stopped at a cummulative dose of 450mg/m2.
This shows the risk of cardiomyopathy in AVA6000 compared to current treatment dosage is already looking very small.
GLA